Peter Powchik, SVP Clinical Development & Reg at REGENERON PHARMACEUTICALS INC (REGN), sold 21,625 shares at $270.00 ($5.9M) on 2013-12-17, disclosed to the SEC on 2013-12-17.
Scheduled sale ($5.9M) by SVP Clinical Development & Reg under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $272.73 | 898 | $245K | 4.2% |
| 2 | $272.73 | 1,526 | $416K | 7.1% |
| 3 | $272.73 | 2,588 | $706K | 12.0% |
| 4 | $272.73 | 3,338 | $910K | 15.4% |
| 5 | $272.73 | 3,662 | $999K | 16.9% |
| 6 | $272.73 | 9,605 |
| $2.6M |
| 44.4% |
| 7 | $270.00 | 8 | $2K | 0.0% |
| Total | $272.73 avg | 21,625 | $5.9M | 100% |
| Filing → |
| REGN | SELL | 2014-01-03 | $5.7M | — | Filing → |
| REGN | SELL | 2013-12-20 | $2.5M | — | Filing → |
| REGN | SELL | 2013-01-04 | $2.5M | — | Filing → |